Why the study?
Does a glycopyrrolate-neostigmine mixture improve safety (reduce arrhythmias and bradycardia) compared to an atropine-neostigmine mixture during curarization reversal in pediatric patients with congenital cardiac disease?
Does a glycopyrrolate-neostigmine mixture improve safety (reduce arrhythmias and bradycardia) compared to an atropine-neostigmine mixture during curarization reversal in pediatric patients with congenital cardiac disease?
Glycopyrrolate does not appear safer than atropine for curarization reversal in pediatric patients with congenital cardiac disease due to a higher incidence of arrhythmias.
Greater arrhythmia incidence with glycopyrrolate may favor atropine for reversal in these children; observational data leave choice open for randomized trials.
Electrocardiographic findings during curarization reversal with a glycopyrrolate-neostigmine mixture were compared to those with an atropine-neostigmine mixture in pediatric patients with congenital cardiac disease. Both giycopyrrolate and atropine afforded equal protection against the bradycardiac effects of neostigmine but the incidence of arrhythmias was greater with giycopyrrolate. Giycopyrrolate does not seem safer than atropine for such procedures.
No takes yet. Share an insight, caveat, or question.
WONG et al. (1974) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: